Alpha-1 Antitrypsin Deficiency (AATD) Market to Register Sustainable Growth During the Forecast Period (2023-2032) – DelveInsight | Key Companies – Alnylam, AstraZeneca, Grifols, Kamada, Mereo

Alpha-1 Antitrypsin Deficiency (AATD) Market to Register Sustainable Growth During the Forecast Period (2023-2032) - DelveInsight | Key Companies - Alnylam, AstraZeneca, Grifols, Kamada, Mereo
Delveinsight Business Research LLP
In the 7MM, the Alpha-1 Antitrypsin Deficiency (AATD) Market size was approximately USD 1,200 million in 2021, which is expected to grow by 2032. As per DelveInsight, the Alpha-1 Antitrypsin Deficiency Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases and the launch of new therapies in the market.

DelveInsight’s “Alpha-1 Antitrypsin Deficiency (AATD) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Alpha-1 Antitrypsin Deficiency market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Alpha-1 Antitrypsin Deficiency drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Alpha-1 Antitrypsin Deficiency treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Alpha-1 Antitrypsin Deficiency (AATD): An Overview

According to the National Organization for Rare Disorders (NORD), alpha-1 antitrypsin deficiency (AATD) is a rare hereditary (autosomal recessive) metabolic disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT), found in the blood. It can cause chronic obstructive pulmonary obstructive disease (COPD); COPD may often have emphysema symptoms. Besides, few adults with AATD develop liver damage (cirrhosis) due to the formation of scar tissue in the liver.

The etiology and pathogenesis of AATD involve a complex interaction between genetic and environmental factors resulting in immune-mediated reactions affecting the lungs, liver, and skin. The disease is due to variants in the SERPINA1 gene. However, because most AATD cases are unrecognized, the disorder is underdiagnosed.

Alpha-1 Antitrypsin Deficiency (AATD) Market Key Facts

  • In 2022, the total prevalent cases of AATD in the 7MM were estimated to be nearly 194,000, of which the United States observed the highest number of cases (close to 117,000 cases). The EU4 and the UK countries accounted for more than 77,000 prevalent cases.

  • In 2022, among the EU4 and the UK, the total diagnosed cases of AATD were highest in the UK (3,000+ cases) followed by Germany (~2,700 cases), which are expected to rise during the forecast period.

  • According to DelveInsight’s analysts, in 2022, the total diagnosed cases of AATD in the US were over 15,400, and nearly 8,300 in the EU4 and the UK, which are expected to rise during the forecast period (2023–2032).

Alpha-1 Antitrypsin Deficiency (AATD) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Alpha-1 Antitrypsin Deficiency pipeline therapies. It also thoroughly assesses the Alpha-1 Antitrypsin Deficiency market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the market trend for each marketed Alpha-1 Antitrypsin Deficiency drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Alpha-1 Antitrypsin Deficiency (AATD) Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Alpha-1 Antitrypsin Deficiency epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Alpha-1 Antitrypsin Deficiency epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Alpha-1 Antitrypsin Deficiency (AATD) Epidemiology, Segmented as –

  • Total Prevalent Cases of AATD [2019–2032]

  • Total Diagnosed Prevalent Cases of AATD [2019–2032]

  • Genotype-specific Diagnosed Prevalent Cases of AATD [2019–2032]

  • Symptom-specific Prevalent Cases of AATD [2019–2032]

  • Comorbidity-specific Diagnosed Prevalent Cases of AATD [2019–2032]

Alpha-1 Antitrypsin Deficiency Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Alpha-1 Antitrypsin Deficiency market or expected to be launched during the study period. The analysis covers the Alpha-1 Antitrypsin Deficiency market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Alpha-1 Antitrypsin Deficiency drugs based on their sale and market share.

The report also covers the Alpha-1 Antitrypsin Deficiency pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Alpha-1 Antitrypsin Deficiency companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Alpha-1 Antitrypsin Deficiency Market Will Evolve and Grow by 2032 @

Alpha-1 Antitrypsin Deficiency (AATD) Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Alpha-1 Antitrypsin Deficiency. Currently, Deerland Probiotics & Enzymes is leading the therapeutics market with its Alpha-1 Antitrypsin Deficiency drug candidates in the most advanced stage of clinical development.

Alpha-1 Antitrypsin Deficiency (AATD) Companies Actively Working in the Therapeutics Market Include

  • Alnylam Pharmaceuticals

  • Arrowhead Pharmaceuticals

  • AstraZeneca

  • CSL Behring

  • Dicerna Pharmaceuticals

  • Grifols

  • Kamada, Ltd

  • LFB Biotechnologies

  • Mereo Biopharma

  • Octapharma

  • Shire

  • Vertex Pharmaceuticals

And Many Others

Emerging and Marketed Alpha-1 Antitrypsin Deficiency (AATD) Therapies Covered in the Report Include:

  • ALN-AAT02: Alnylam Pharmaceuticals

  • Alvelestat: Mereo Biopharma

  • ARO-AAT: Arrowhead Pharmaceutical

  • Inhaled AAT: Kamada

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Alpha-1 Antitrypsin Deficiency Competitive Intelligence Analysis

4. Alpha-1 Antitrypsin Deficiency Market Overview at a Glance

5. Alpha-1 Antitrypsin Deficiency Disease Background and Overview

6. Alpha-1 Antitrypsin Deficiency Patient Journey

7. Alpha-1 Antitrypsin Deficiency Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Alpha-1 Antitrypsin Deficiency Treatment Algorithm, Current Treatment, and Medical Practices

9. Alpha-1 Antitrypsin Deficiency Unmet Needs

10. Key Endpoints of Alpha-1 Antitrypsin Deficiency Treatment

11. Alpha-1 Antitrypsin Deficiency Marketed Therapies

12. Alpha-1 Antitrypsin Deficiency Emerging Drugs and Latest Therapeutic Advances

13. Alpha-1 Antitrypsin Deficiency Seven Major Market Analysis

14. Attribute Analysis

15. Alpha-1 Antitrypsin Deficiency Market Outlook (In US, EU5, and Japan)

16. Alpha-1 Antitrypsin Deficiency Companies Active in the Market

17. Alpha-1 Antitrypsin Deficiency Access and Reimbursement Overview

18. KOL Views on the Alpha-1 Antitrypsin Deficiency Market

19. Alpha-1 Antitrypsin Deficiency Market Drivers

20. Alpha-1 Antitrypsin Deficiency Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Reports by DelveInsight 

Injectable Drug Delivery Devices Market

The Global Injectable Drug Delivery Devices Market was valued at USD 19.63 billion in 2021, growing at a CAGR of 11.26% during the forecast period from 2023 to 2028, to reach USD 37.22 billion by 2028. The demand for Injectable Drug Delivery Devices is primarily witnessing growth on account of the increasing incidences of chronic conditions such as cancer, diabetes, and cardiovascular disorders among others, the increase in demand for self-injectors, the increase in biologics and biosimilar market, the rising need and demand for patient compliance to treatment and the rising innovations and technological advancement in this arena.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States